Prebiom
The aim of this study is to build a reliable model that can predict the group of patients that are likely to respond best to Immune Checkpoint Inhibitors (ICI), and who should proceed with immunotherapy, whilst also predicting the group of patients that are unlikely to respond to immunotherapy, and where alternative avenues of treatment should be explored.